focus -WSS

focus

author：hotspot 2025-10-01 17:20:09 - browse：52988

Alzheimer’s disease has killed at least three women in Astrida Schaeffer’s family over two generations, leaving her feeling helpless and bereft.

The first was her Polish-born maternal grandmother, who began showing symptoms when Schaeffer started college in 1981 and died seven years later. Then came her mother, a onetime Fulbright Scholar and high school language teacher who had been fluent in five languages but lost the ability to speak. She died in 2019. Last year, the disease killed Schaeffer’s mother’s sister, a former lab technician for Johnson & Johnson.

Schaeffer, a 59-year-old costume historian in North Berwick, Maine, has no symptoms of Alzheimer’s. But in 2021 her family history led her to apply to join a clinical trial testing a drug on people at risk for developing them. To participate, volunteers couldn’t have cognitive impairment. But they needed to test positive for a biomarker that put them at higher risk for mental decline ― deposits of a sticky toxic protein in the brain called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Juul spent big to court Black leaders to promote its e

focus

WSS

Quicker fix for pulse oximeters urged during FDA public meeting

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

ARCH Venture Partners is raising $3 billion for a life sciences fund

What we need to know about Arena Bioworks

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Data don't support strong claims for Covid

hotspot

focus

leisure time

Activists slam private health insurers over coverage restrictions

FDA drug safety: Singulair case shows systemic surveillance flaws

Drug repurposing or repositioning? The language matters

Juul spent big to court Black leaders to promote its e

In age of alternative facts, a scholarly course on calling out crap

The real point of Kenneth Smith’s execution by nitrogen gas

How one medical school became remarkably diverse

FTC loses bid to block Novant's North Carolina hospital merger

Psychedelics group wrestles with new pharma identity

FDA approves Moderna’s RSV vaccine, its second licensed product

explore

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Anthony Fauci pushes back on GOP claims during Covid hearing

Time to name cancers by genetics, not organ of origin, expert says

Structure Therapeutics oral GLP

ASCO Daily Recap: CAR

Cybersecurity threat forces Lurie Children's to take systems offline

focus

Wikipedia

focus

explore